International professional education covering cannabinoid science, clinical practice, evidence, and regulatory frameworks — for healthcare professionals, researchers and policy leaders worldwide.
The Institute for Cannabinoid Therapy is an independent international educational organisation bringing together clinicians, scientists and regulatory experts from multiple jurisdictions. Together, they build a rigorous, evidence-based curriculum that advances the safe and responsible practice of cannabinoid therapeutics.
The evidence base for cannabinoid therapeutics is expanding at unprecedented pace.
Patients and colleagues are asking informed questions in every specialty.
Regulatory landscapes are shifting across most major jurisdictions.
Rigorous appraisal is essential to separate signal from noise.
Understanding benefits, limitations, contraindications and interactions.
A structured introduction to cannabinoid science, pharmacology, and clinical fundamentals for healthcare practitioners.
Focused, self-paced modules across pharmacology, cannabinoids and clinical indications.
Premium live teaching on pain, complex cases, emerging research, expert panels, regulation and clinical pearls.
Members join a network of clinicians and researchers with year-round access to education, discussion and expert-led events.
Continually updated educational reviews comparing prescribing frameworks, product access, practitioner responsibilities and evolving evidence across major jurisdictions.
TGA Special Access and Authorised Prescriber pathways; unregistered medicine framework.
Federal vs. state divergence; FDA-approved cannabinoids and state-level medical programs.
Health Canada Cannabis Regulations and prescribing under the Access to Cannabis for Medical Purposes framework.
Unlicensed specials on the NHS and private specialist prescribing under Schedule 2.
BfArM oversight, statutory insurance reimbursement and evolving pharmacy dispensing rules.
Ministry of Health authorisation, regional access pathways and magistral preparations.
Swissmedic regulation, recent legal reforms and physician-led access schemes.
Medicinal Cannabis Scheme, minimum quality standards and prescribing responsibilities.
Comparative overview of frameworks across Argentina, Brazil, Colombia, Chile and Uruguay.
Regulations change frequently. Practitioners remain responsible for understanding and complying with local laws applicable to their jurisdiction and scope of practice.
Cannabinoid receptor pharmacology researcher with two decades in translational neuroscience.
Consultant pain physician and honorary professor; clinical trial investigator in cannabinoid analgesia.
Rural GP and clinical educator with a focus on responsible prescribing and patient safety frameworks.
Hospital pharmacist and lecturer; author of national cannabinoid formulary guidance.
Palliative care physician contributing to European clinical guidance on cannabinoid therapeutics.
Advisor on European regulatory frameworks for medicinal cannabis and cannabinoid research.
Enrol in the Foundations Program or explore individual modules. Membership unlocks year-round education, community and regulatory intelligence.
